

Annette Bruchfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7062567/publications.pdf>

Version: 2024-02-01

114
papers

5,560
citations

117619

34
h-index

82542

72
g-index

114
all docs

114
docs citations

114
times ranked

5708
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetically Distinct Subsets within ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2012, 367, 214-223.	27.0	820
2	Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. <i>Lancet</i> , 2015, 386, 1537-1545.	13.7	625
3	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 955-960.	0.9	348
4	High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. <i>Hepatology</i> , 2005, 41, 275-279.	7.3	207
5	Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2011, 57, 566-574.	1.9	179
6	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.9	165
7	Cholinergic Anti-Inflammatory Pathway Activity and High Mobility Group Box-1 (HMGB1) Serum Levels in Patients with Rheumatoid Arthritis. <i>Molecular Medicine</i> , 2007, 13, 210-215.	4.4	162
8	Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1573-1580.	0.7	147
9	Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. <i>Journal of Viral Hepatitis</i> , 2006, 13, 316-321.	2.0	140
10	Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection – a pilot study. <i>Journal of Viral Hepatitis</i> , 2001, 8, 287-292.	2.0	139
11	Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 701-708.	2.0	131
12	Hepatitis C Infection, Time in Renal-Replacement Therapy, and Outcome after Kidney Transplantation. <i>Transplantation</i> , 2004, 78, 745-750.	1.0	123
13	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
14	High Mobility Group Box Protein-1 Correlates with Renal Function in Chronic Kidney Disease (CKD). <i>Molecular Medicine</i> , 2008, 14, 109-115.	4.4	92
15	COVID-19 vaccines and kidney disease. <i>Nature Reviews Nephrology</i> , 2021, 17, 291-293.	9.6	91
16	Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. <i>Journal of Viral Hepatitis</i> , 2004, 11, 84-87.	2.0	88
17	The COVID-19 pandemic: consequences for nephrology. <i>Nature Reviews Nephrology</i> , 2021, 17, 81-82.	9.6	81
18	Whole blood cytokine attenuation by cholinergic agonists <i>ex vivo</i> and relationship to vagus nerve activity in rheumatoid arthritis. <i>Journal of Internal Medicine</i> , 2010, 268, 94-101.	6.0	78

#	ARTICLE	IF	CITATIONS
19	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1128-1135.	4.5	75
20	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1125-1130.	0.9	72
21	Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4â€“5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 585-594.	8.1	71
22	Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R36.	3.5	64
23	Macrophage Migration Inhibitory Factor Mediates Hypoxia-Induced Pulmonary Hypertension. <i>Molecular Medicine</i> , 2012, 18, 215-223.	4.4	63
24	Rituximab Treatment for Relapsing Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Systematic Review. <i>American Journal of Nephrology</i> , 2014, 39, 322-330.	3.1	55
25	Rituximab for minimal change disease in adults: long-term follow-up. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 851-856.	0.7	54
26	Determination of Ribavirin in Serum Using Highly Selective Solid-Phase Extraction and High-Performance Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 215-218.	2.0	54
27	High-Mobility Group Box-1 Protein (HMGB1) Is Increased in Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis with Renal Manifestations. <i>Molecular Medicine</i> , 2011, 17, 29-35.	4.4	53
28	Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 84-91.	0.7	52
29	Elevated Serum Macrophage Migration Inhibitory Factor (MIF) Concentrations in Chronic Kidney Disease (CKD) Are Associated with Markers of Oxidative Stress and Endothelial Activation. <i>Molecular Medicine</i> , 2009, 15, 70-75.	4.4	50
30	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <i>Liver International</i> , 2020, 40, 1032-1041.	3.9	44
31	Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. <i>Journal of Hepatology</i> , 2018, 68, 904-911.	3.7	42
32	Interferon Therapy for HCV-Associated Glomerulonephritis: Meta-Analysis of Controlled Trials. <i>International Journal of Artificial Organs</i> , 2007, 30, 212-219.	1.4	41
33	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 719-727.	0.7	41
34	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.8	39
35	Mild cognitive impairment and kidney disease: clinical aspects. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 10-17.	0.7	38
36	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.7	38

#	ARTICLE	IF	CITATIONS
37	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	5.8	37
38	Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 116-119.	1.1	32
39	C5a receptor inhibitor avacopan in immunoglobulin A nephropathyâ€”an open-label pilot study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 922-928.	2.9	30
40	Late-onset neutropenia after rituximab in ANCA-associated vasculitis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 404-407.	1.1	28
41	Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2059-2072.	0.7	28
42	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1112-1114.	0.7	27
43	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii33-ii44.	0.7	26
44	Macrophage Migration Inhibitory Factor in Clinical Kidney Disease. <i>Frontiers in Immunology</i> , 2016, 7, 8.	4.8	25
45	Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii23-ii32.	0.7	25
46	The COVID-19 pandemic and ANCA-associated vasculitis â€” reports from the EUVAS meeting and EUVAS education forum. <i>Autoimmunity Reviews</i> , 2021, 20, 102986.	5.8	25
47	B cellâ€”depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, sfw106.	2.9	24
48	Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and preâ€”existing renal disease. <i>Hepatology Research</i> , 2017, 47, 1340-1345.	3.4	24
49	The cholinergic anti-inflammatory pathway in chronic kidney diseaseâ€”review and vagus nerve stimulation clinical pilot study. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1840-1852.	0.7	23
50	Acute kidney injury and mortality risk in older adults with COVID-19. <i>Journal of Nephrology</i> , 2021, 34, 295-304.	2.0	23
51	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 829-838.	6.1	23
52	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibodyâ€”associated vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1684-1687.e10.	2.9	22
53	ERA-EDTA invests in transformation to greener health care. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 901-903.	0.7	21
54	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410.	0.7	21

#	ARTICLE	IF	CITATIONS
55	The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3112-3116.	0.7	20
56	Serum Retinol-Binding Protein Concentration and Its Association with Components of the Uremic Metabolic Syndrome in Nondiabetic Patients with Chronic Kidney Disease Stage 5. <i>American Journal of Nephrology</i> , 2009, 29, 447-453.	3.1	17
57	Rituximab in Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis. <i>Nephron Clinical Practice</i> , 2015, 128, 277-282.	2.3	16
58	Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii4-ii12.	0.7	16
59	Gamma Glutamyltranspeptidase Activity and Viral Hepatitis in Dialysis Population. <i>International Journal of Artificial Organs</i> , 2007, 30, 6-15.	1.4	15
60	Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2051-2057.	0.7	15
61	Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists. <i>Kidney International Reports</i> , 2021, 6, 1197-1199.	0.8	15
62	Microparticles Expressing Myeloperoxidase and Complement C3a and C5a as Markers of Renal Involvement in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 714-721.	2.0	14
63	Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii55-ii62.	0.7	14
64	Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 920-925.	0.7	14
65	Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease. <i>Kidney International Reports</i> , 2017, 2, 1208-1218.	0.8	13
66	Cholinergic anti-inflammatory pathway activity in dialysis patients: a role for neuroimmunomodulation?. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 599-605.	2.9	12
67	The COVID-19 Epidemic: Management and Outcomes of Hemodialysis and Peritoneal Dialysis Patients in Stockholm, Sweden. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 250-256.	2.0	12
68	First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2021, 23, 211.	3.5	12
69	Nomenclature in nephrology: preserving 'renal' and 'nephro' in the glossary of kidney health and disease. <i>Journal of Nephrology</i> , 2021, 34, 639-648.	2.0	11
70	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1758-1760.	0.7	11
71	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii14-ii23.	0.7	11
72	The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation. <i>Molecular Medicine</i> , 2019, 25, 39.	4.4	10

#	ARTICLE	IF	CITATIONS
73	Microparticles expressing myeloperoxidase as potential biomarkers in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). <i>Journal of Molecular Medicine</i> , 2020, 98, 1279-1286.	3.9	10
74	Nephrology: achieving sustainability. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2030-2033.	0.7	10
75	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 23-35.	2.9	10
76	The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 551-561.	0.7	10
77	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. <i>Kidney360</i> , 2022, 3, 293-306.	2.1	10
78	Pegylated interferon and ribavirin in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1444-1445.	0.7	9
79	Macrophage Migration Inhibitory Factor (MIF) and Thyroid Hormone Alterations in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV). <i>Molecular Medicine</i> , 2013, 19, 109-114.	4.4	9
80	Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition?. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa056.	0.7	9
81	Scoring of medial arterial calcification predicts cardiovascular events and mortality after kidney transplantation. <i>Journal of Internal Medicine</i> , 2022, 291, 813-823.	6.0	9
82	Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia. <i>Journal of Hepatology</i> , 2006, 44, 432-433.	3.7	8
83	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1469-1480.	0.7	8
84	Rituximab in minimal change disease and focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 983-985.	0.7	8
85	Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA. <i>Rheumatology</i> , 2022, 61, 3461-3470.	1.9	8
86	The management of membranous nephropathy – an update. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1033-1042.	0.7	7
87	Funding kidney research as a public health priority: challenges and opportunities. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.7	6
88	Brain dysfunction in tubular and tubulointerstitial kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii46-ii55.	0.7	6
89	Renal-limited vasculitis in children: a single-center retrospective long-term follow-up analysis. <i>Clinical Nephrology</i> , 2013, 80, 388-394.	0.7	6
90	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2020, 47, 580-588.	2.0	5

#	ARTICLE	IF	CITATIONS
91	Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab151.	0.6	5
92	Pentraxin-3 â€œ a potential biomarker in ANCA-associated vasculitis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 293-301.	1.1	5
93	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1077-1082.	0.7	4
94	Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. <i>Seminars in Dialysis</i> , 2019, 32, 135-140.	1.3	4
95	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 4-6.	0.7	4
96	Paving the way towards gender equality: how are we faring in nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 552-554.	0.7	4
97	Observational study of risk factors associated with clinical outcome among elderly kidney transplant recipients in Sweden â€œ a decade of follow-up. <i>Transplant International</i> , 2021, 34, 2363-2370.	1.6	4
98	Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemiaâ€”anti-viral therapy vs rituximab. <i>Rheumatology</i> , 2006, 45, 783-784.	1.9	3
99	Rituximab for Multirelapsing, Steroid-Dependent or Steroid-Resistant, Minimal-Change Nephropathy â€œ a Report of Nine Adult Cases. <i>Nephrology Research & Reviews</i> , 2010, 2, 8-11.	0.2	3
100	The role of Dendrin in IgA Nephropathy. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	3
101	The nephrology crystal ball: the medium-term future. <i>Nephrology Dialysis Transplantation</i> , 2019, 35, 222-226.	0.7	2
102	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 437-442.	2.9	1
103	019.â€¢PENTRAXIN-3 PLASMA LEVELS AND GENE POLYMORPHISMS IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	1
104	HCV eradication in chronic kidney disease: ready for prime time?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 880-882.	8.1	1
105	Is There Decreasing Public Interest in Renal Transplantation? A Google TrendsTM Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1048.	2.4	1
106	The Influence of C-Hepatitis on C-Reactive Protein in a Cohort of Brazilian Hemodialysis Patients. <i>Hemodialysis International</i> , 2004, 8, 102-102.	0.9	0
107	P0347COMPLEMENT FACTOR BB AND FACTOR C4D IN IGA NEPHROPATHY AND IGA VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
108	POS1230â€¢...OUTCOME FOLLOWING COVID-19 INFECTION IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 898.2-898.	0.9	0

#	ARTICLE	IF	CITATIONS
109	OP0003â€¦AUTOREACTIVE CD4+ T CELLS AND THEIR TCR REPERTOIRE IN PR3-ANCA ASSOCIATED VASCULITIS. Annals of the Rheumatic Diseases, 2021, 80, 1.3-1.	0.9	0
110	MO358ACUTE KIDNEY INJURY AND MORTALITY RISK IN OLDER ADULTS WITH AND WITHOUT COVID-19: DATA FROM GEROCOVID STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
111	OP0052â€¦Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody â€œ associated vasculitis. , 2018, , .		0
112	Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations. African Journal of Nephrology, 2020, 23, 159-168.	0.1	0
113	Present and future of CONNECT: a new and compelling project of modern medicine. Nephrology Dialysis Transplantation, 2021, 37, ii1-ii3.	0.7	0
114	FC047: RNA Sequencing of Microdissected Kidney Biopsies from IGA Nephropathy Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0